ID   PC-9/GR6
AC   CVCL_DI32
SY   PC-9 GR6
DR   cancercelllines; CVCL_DI32
DR   GEO; GSM481166
DR   Progenetix; CVCL_DI32
DR   Wikidata; Q54938499
RX   PubMed=20118985;
CC   Population: Chinese; Han and Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified; Note=Responsible for gefitinib resistance (PubMed=20118985).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 15
//
RX   PubMed=20118985; DOI=10.1038/onc.2009.526; PMCID=PMC2859699;
RA   Ercan, Dalia
RA   Zejnullahu, Kreshnik
RA   Yonesaka, Kimio
RA   Xiao, Yun
RA   Capelletti, Marzia
RA   Rogers, Andrew
RA   Lifshits, Eugene
RA   Brown, Alison
RA   Lee, Charles
RA   Christensen, James Gail
RA   Kwiatkowski, David Joseph
RA   Engelman, Jeffrey Adam
RA   Janne, Pasi Antero
RT   "Amplification of EGFR T790M causes resistance to an irreversible EGFR
RT   inhibitor.";
RL   Oncogene 29:2346-2356(2010).
//